Advertisement

Trametinib (GSK1120212)

  • Robert Zeiser
  • Hana Andrlová
  • Frank Meiss
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 211)

Abstract

The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a critical role in the regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis. Therefore, MEK inhibition was recognized as a promising target for antineoplastic therapy. Trametinib (GSK1120212), an oral MEK inhibitor which is selective for MEK1 and MEK2, has been approved by the FDA for the treatment of metastatic melanoma in a combination with a BRAF inhibitor. In this overview, preclinical and clinical data for trametinib are presented including mechanisms based on in vitro studies as well as findings from different clinical studies. The future clinical trial in different solid tumor entities will define the therapeutic role of this targeted therapy approach, possibly as a combination with other targeted therapies such as BRAF inhibitors.

Keywords

MAPK/ERK Kinase (MEK) Trametinib Small molecules Kinase inhibition 

References

  1. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 6:37–40CrossRefGoogle Scholar
  2. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefGoogle Scholar
  3. Fedorenko IV, Paraiso KH, Smalley KS (2011) Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82:201–209CrossRefPubMedPubMedCentralGoogle Scholar
  4. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012a) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703CrossRefPubMedPubMedCentralGoogle Scholar
  5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012b) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114CrossRefPubMedGoogle Scholar
  6. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG et al (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 6:989–1000CrossRefGoogle Scholar
  7. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM (2010) A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16:2450–2457CrossRefPubMedGoogle Scholar
  8. Honecker F, Wermann H, Mayer F, Gillis AJM et al (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumours. J Clin Oncol 27:2129–2136CrossRefPubMedGoogle Scholar
  9. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C et al (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. J Clin Oncol 6:773–781Google Scholar
  10. Infante JR, Papadopoulos KP, Bendell JC, Patnaik A, Burris HA, Rasco D et al (2013) A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer 49:2077–2085CrossRefPubMedGoogle Scholar
  11. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E et al (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720–729CrossRefPubMedGoogle Scholar
  12. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972CrossRefPubMedPubMedCentralGoogle Scholar
  13. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA et al (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482–489CrossRefPubMedGoogle Scholar
  14. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555–567CrossRefPubMedGoogle Scholar
  15. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Eng J Med 377:1813–1823CrossRefGoogle Scholar
  16. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281–5293CrossRefPubMedGoogle Scholar
  17. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924–1937CrossRefPubMedGoogle Scholar
  18. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68:4853–4861CrossRefPubMedPubMedCentralGoogle Scholar
  19. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977CrossRefPubMedPubMedCentralGoogle Scholar
  20. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Eng J Med 372:30–39CrossRefGoogle Scholar
  21. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308CrossRefPubMedGoogle Scholar
  22. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362CrossRefPubMedGoogle Scholar
  23. Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 6:350–356CrossRefGoogle Scholar
  24. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683–695CrossRefPubMedPubMedCentralGoogle Scholar
  25. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885CrossRefPubMedGoogle Scholar
  26. Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R (2014) BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest 124:5074–5084CrossRefPubMedPubMedCentralGoogle Scholar
  27. Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T (2011) Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 39:23–31PubMedGoogle Scholar
  28. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576–1583CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany
  2. 2.Department of Dermatology and Venereology, Medical Center - University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations